Objectives: To develop and validate algorithms to define statin intolerance (SI) in an administrative database using electronic medical records (EMRs) as the reference comparison. Methods: One thousand adults with one or more qualifying changes in statin therapy and one or more previous diagnoses of hyperlipidemia, hypercholesterolemia, or mixed dyslipidemia were identified from the Henry Ford Health System administrative database. Data regarding statin utilization, comorbidities, and adverse effects were extracted from the administrative database and corresponding EMR. Patients were stratified by cardiovascular (CV) risk. SI was classified as absolute intolerance or titration intolerance on the basis of changes in statin utilization and/or the occurrence of adverse effects and laboratory testing for creatine kinase. Measures of concordance (Cohen's kappa [κ]) and accuracy (sensitivity, specificity, positive predictive value [PPV], and negative predictive value) were calculated for the administrative database algorithms. Results: Half of the sample population was white, 52.9% were women, mean age was 60.6 years, and 35.7% were at high CV risk. SI was identified in 11.5% and 14.0%, absolute intolerance in 2.2% and 3.1%, and titration intolerance in 9.7% and 11.8% of the patients in the EMR and the administrative database, respectively. The algorithm identifying any SI had substantial concordance (κ ¼ 0.66) and good sensitivity (78.1%), but modest PPV (64.0%). The titration intolerance algorithm performed better (κ ¼ 0.74; sensitivity 85.4%; PPV 70.1%) than the absolute intolerance algorithm (κ ¼ 0.40; sensitivity 50%; PPV 35.5%) and performed best in the high CV-risk group (n ¼ 353), with robust concordance (κ ¼ 0.73) and good sensitivity (80.9%) and PPV (75.3%). Conclusions: Conservative but comprehensive algorithms are available to identify SI in administrative databases for application in real-world research. These are the first validated algorithms for use in administrative databases available to decision makers.
Introduction
Research has consistently demonstrated that statins decrease both the risk for cardiovascular (CV) events and mortality rates in patients with hypercholesterolemia [1, 2] . Consequently, contemporary lipid management guidelines recommend statin therapy for patients with increased CV risk who are most likely to benefit in terms of atherosclerotic cardiovascular disease (ASCVD) risk reduction. The American College of Cardiology/American Heart Association guidelines identify four major statin benefit groups: 1) individuals with clinical ASCVD, 2) individuals with elevated low-density lipoprotein cholesterol (LDL-C; Z190 mg/dl), 3) individuals with diabetes and increased LDL-C (70-189 mg/dl), and 4) individuals with estimated 10-year ASCVD risk of 7.5% or higher [3] . The National Lipid Association (NLA) recommends moderate-to high-intensity statin therapy for patients with ASCVD or diabetes mellitus, regardless of baseline lipid levels [4] .
Despite the known benefits of statins, many patients, including those at high CV risk, discontinue treatment [5] . Experiencing statin-related adverse effects (AEs) is one of the most common reasons for statin switching or discontinuation [6] . Even among adherent patients, providers may not always be able to prescribe the preferred therapeutic dose as AE frequency increases with dose intensity [7, 8] . The most common statin-associated AEs are muscle-related, and these have been documented in 16.0% to 32.9% of patients receiving statins and in 15.4% to 33.2% of placebo-treated patients in long-term randomized clinical trials [9] . A number of other AEs, however, have been associated with statin therapy, including elevated transaminase, headache, insomnia, fatigue, dyspepsia, nausea, rash, alopecia, constipation, diarrhea, gastrointestinal disturbance, arthritis, and renal disorders [10] [11] [12] . Studies have estimated the incidence or prevalence of muscle-related symptoms (5%-25%), but these data are from clinical trials, single-site retrospective cohort studies, and patient surveys and as such may have limited generalizability to the larger population [6, [13] [14] [15] [16] [17] [18] . Factors associated with increased risk of statin intolerance (SI) include advanced age, clinical or subclinical hypothyroidism, and pre-existing liver or chronic kidney disease [19] .
Although SI is recognized as a clinical entity, there is no consensus yet on a single definition [19, 20] , making it difficult to assess the incidence of SI. The Canadian Working Group (CWG) has defined SI as a clinical syndrome characterized by inability to use statins for long-term reduction of lipids and/or CV risk because of significant symptoms and/or biomarker abnormalities that can be temporally attributed to the initiation or dose escalation of statins; if appropriate, drug withdrawal and rechallenge can strengthen the association. [ 
21(p1553)]
The NLA defines SI as a clinical syndrome characterized by the inability to tolerate at least 2 statins: one statin at the lowest starting daily dose AND another statin at any daily dose, due to either objectionable symptoms (real or perceived) or abnormal lab determinations, which are temporally related to statin treatment and reversible upon statin discontinuation, but reproducible by re-challenge, with other known determinants being excluded. [22(pS78)] These definitions, although similar in many respects, differ in terms of mandating statin dosage and rechallenge and also with respect to the validity of patient symptoms.
Accurate identification of SI is important in terms of both establishing its incidence and characterizing the associated clinical, economic, and quality-of-life burdens, which are at present unknown. The objective of this study was to develop and validate algorithms to identify patients with SI in an administrative database on the basis of the overlap between CWG and NLA definitions.
Methods

Data Source
The data source selected to develop and validate the SI algorithms was from the Henry Ford Health System (HFHS). The HFHS offers primary, acute, and specialty care services in the Midwest and also includes a wholly owned nonprofit health maintenance organization, the Health Alliance Plan (HAP). HFHS data repositories include both an administrative database, which provides comprehensive medical billing and pharmacy claims data, and electronic medical records (EMRs), including laboratory results, from all sites of service, linkable for each patient using a lifetime patient identifier. This study was approved by the HFHS institutional review board.
Validation Study Sample
The validation study sample was drawn from the HFHS administrative claims database using the following criteria: adults (Z18 years) who 1) had one or more statin qualifying events between December 1, 2005, and November 30, 2010, 2) were continuously enrolled in HAP for 1 year before and 2 years after the qualifying event, and 3) had one or more diagnoses (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]) of hyperlipidemia (272.4), hypercholesterolemia (272.0), or mixed hyperlipidemia (272.2) before the qualifying event (index) because lipid levels may have been influenced by existing statin therapy.
Qualifying events included statin discontinuation, switch, or a decrease in statin dosage. Statin switch events were eligible only if the patient switched from a high-intensity statin to a lower intensity statin or from a moderate/low-intensity statin to another moderate/low-intensity statin. Definitions of moderate/ low-intensity and high-intensity statins were based on LDL-Clowering capability. A statin was considered of high intensity or high potency if it reduced the LDL-C level from baseline by more than 45% (Table 1) [23, 24] .
If a patient had multiple qualifying events, the first qualifying event that met the eligibility criteria was selected. If the statin medication pattern for an individual patient met the criteria for both moderate/low-intensity and high-intensity statins, only the high-intensity qualifier was selected, although this did not exclude evaluation of the low-intensity statin if it also occurred during the study observation window. Study index was the date of each qualifying event. All patients were observed for 1 year pre-and 2 years postindex.
A sample of 1000 patients was drawn from the pool of eligible patients. Patients were categorized as being at high CV risk if they had two or more ICD-9-CM diagnoses of diabetes, coronary heart disease, or peripheral artery disease in the 12 months before the qualifying event on outpatient claims on different days or a single diagnosis on an inpatient claim. Data on patients' demographic and clinical characteristics, statin utilization, and AEs were extracted electronically from the administrative database. Statin utilization and AEs data were simultaneously abstracted from the EMR by three trained and credentialed research associates, after completion of a pilot study. Patients with unresolvable conflicts in the EMR or data quality issues in pharmacy claims were excluded from the study.
Statin Utilization and AEs
Statin exposure windows were created to characterize statin utilization and to identify associated AEs. Exposure windows were created independently on the basis of the statin regimen (statin plus dose) prescribed in the EMR as well as on statin fill records from pharmacy data in the administrative database. If present during an exposure window, SI was identified and confirmed.
The following information was abstracted from the EMR: statin prescription dates and dosage, AE type and date, whether changes in prescription were linked to an AE, and the primary and secondary reasons for statin discontinuation or dose lowering, if applicable. A prescription was end-dated if there was an absence of documentation for more than 12 months. Prescription records were then collapsed if the statin name and dosage were unchanged.
Statin exposure windows based on the administrative data relied on pharmacy claims. Periods of continuous use for each statin regimen were identified, allowing for a 30-day gap in the daily drug coverage pattern. In addition, a 45-day grace period was appended to the end of the exposure window for each statin regimen to account for verbal changes in physician instruction that were not reflected in the pharmacy claims records.
A list of AEs (primary and secondary) related to statin use was compiled (Table 2 ) [10] [11] [12] . The occurrence of an AE was based on the documentation of either the clinical term or the ICD-9-CM diagnosis code for an eligible AE in the EMR and independently based solely on the documentation of an ICD-9-CM diagnosis code for one of the eligible AEs in administrative data.
SI Definition
The reference definition of SI was based on EMR data. The SI algorithms were based only on administrative data. Statinintolerant patients identified by the administrative database algorithms were then compared with those identified by the EMR reference, and performance of the algorithms was evaluated. The EMR was presumed to be a superior source of information about SI, given the richness of its clinical repository (e.g., text-based office notes with symptom information). In the primary analysis, the complete list of potential AEs was included in the definition of SI, whereas the secondary analysis included only musculoskeletal events ( Table 2 ).
All patients, in both data sources, were classified as absolute statin-intolerant (unable to tolerate any exposure to statins) or titration statin-intolerant (maximum tolerated dosage less than the desired therapeutic dosage). Patients in the study could meet the criteria for both absolute and titration intolerance.
The occurrence of absolute intolerance was predicated on the notion that patients must be rechallenged with a second statin unless the documented AE was rhabdomyolysis, a potentially life-threatening syndrome resulting from the breakdown of skeletal muscle fibers and subsequent release of cellular content into the circulation [25] . Accordingly, in the EMR, absolute intolerance required the following three criteria to be satisfied: 1) the physician discontinues two or more prescriptions for different statin agents (only one in the presence of rhabdomyolysis), 2) the patient never receives another statin prescription (minimum of 100 days of observation remaining postdiscontinuation), and 3) the reason for discontinuation (primary or secondary) is an AE, or an explicit link is documented between the statin and an AE, or the patient is documented as statin-intolerant/allergic.
The absolute intolerance algorithm applied to the administrative database also reflected these principles, requiring that 1) the patient stops filling prescriptions for two or more statin agents (only one in the presence of rhabdomyolysis), 2) the patient never fills another statin prescription (minimum of 100 days of observation remaining), and 3) either an elevated creatine kinase test result or an AE is documented during exposure to the last documented statin.
The occurrence of titration SI was predicated on the supposition that, among patients on high-intensity statin therapy, any reduction in intensity reflects the inability of the patient to tolerate the desired therapeutic statin strength. Accordingly, in the EMR, titration intolerance required the following three criteria to be satisfied: 1) the physician discontinues a prescription for a high-intensity statin and initiates a prescription at a lower level of intensity, 2) either the discontinued high-intensity statin is linked to SI or there is an AE documented during the period of high-intensity exposure, and 3) there is no subsequent prescription for a statin at the original intensity level (minimum of 100 days of observation remaining).
The titration intolerance algorithm that was applied to the administrative database also embodied these principles, requiring that 1) the patient discontinues filling a prescription for a highintensity statin and fills a prescription at a lower level of intensity, 2) no subsequent prescription is filled for a statin at the original intensity level, and 3) there is a minimum of 100 days remaining in the observation window after the lowering of the statin intensity.
Data Analysis
The EMR served as the reference against which the algorithms were evaluated, as is customary in administrative data-based validation studies. Concordance between the reference and the algorithms was measured using Cohen's kappa (κ), a numerical rating of the degree to which the observers (or data sources) agree by chance. Kappa is standardized on a scale of À1 to 1, where * Statins were identified using national drug codes.
1 represents perfect agreement, 0 represents what would be expected by chance, and negative values indicate agreement less than chance [26] . A kappa statistic between 0.41 and 0.60 was used to indicate moderate agreement, 0.61 to 0.80 substantial agreement, and 0.81 to 1.0 almost perfect agreement [27] . In addition, we used traditional tests of diagnostic accuracy to measure the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the algorithms. The algorithms were refined to incorporate new information and expert opinions after the entire medical record was reviewed for patients identified by the algorithms as false-positive or false-negative. The definitions of SI used in the administrative database were subsequently revised to maximize the agreement with the NLA definition of SI [22] and to maximize the concordance and accuracy of the algorithms. Only the final versions of the algorithms are presented. To adjust for HFHS-specific formulary restrictions, a higher percentage of atorvastatin patients (40%) and a lower percentage of simvastatin patients (40%) than observed in the pool of eligible patients were selected to reflect real-world statin use. The remaining 20% of selected patients represent the use of other statins. Because of irreconcilable differences in the medical records, 10 patients (1%) were excluded from the study after data abstraction. Table 3 presents the baseline demographic and clinical characteristics of the sample. Half of the sample population was white (49.8%) and half was female (52.9%). Twenty-five percent of the patients resided in an area where the median household income was less than $40,000, whereas 20.6% resided in an area where the median household income was $70,000 or more. Prescriptions for nonstatin lipid-lowering therapy were used infrequently. A total of 353 patients (36%) had baseline evidence of diabetes (27.4%), coronary artery disease (11.7%), or peripheral artery disease (0.6%) and were classified as having high CV risk. Hypertension was the most common comorbidity, identified in 39.9% of the patients at 
Results
Patient Disposition and Characteristics
baseline. In the EMR, the most frequent AEs documented during an episode of statin exposure that was classified as intolerant were other muscle toxicity (19.8%), myalgia or myositis (18.4%), arthralgia (12.8%), and rash (11.3%) (see 
SI and Algorithm Concordance
In the primary analysis, 11.5% of the patients (n ¼ 114) were identified in the EMR as statin-intolerant compared with 14.0% of the patients (n ¼ 139) in the administrative database ( Table 4) . The proportion of patients identified as statin-intolerant was twice as high among patients at high CV risk as it was among those at low CV risk. Titration intolerance occurred in 16.7% and 5.8% of the patients in the EMR and in 18.7% and 8.0% of the patients in the administrative database in high and low CV-risk groups, respectively. Few patients were identified as absolute intolerant in either high or low CV-risk groups. The frequency of SI in the secondary analysis was lower but not notably so (Table 5 ). It should be noted that these frequencies cannot be used as proxies for SI incidence in the general population because the study was not conducted on a random sample of statin users. Although rates of SI in the EMR and the administrative database were similar, the algorithms did not always identify the same patients as intolerant. Generally, the algorithm identifying any SI demonstrated high levels of overall agreement (92.4%), substantial concordance (κ ¼ 0.66), and good sensitivity (78.1%), but modest PPV (64.0%), reflecting differences in the accuracy of the algorithm associated with detecting absolute and titration intolerance. The absolute intolerance algorithm had notably lower concordance (κ ¼ 0.30-0.56), sensitivity (46%-55%), and PPV (24%-60%) both overall and in each of the CV-risk groups. Both absolute and titration intolerance algorithms performed best in the high CV-risk group. In the high CVrisk group, the titration intolerance algorithm was most robust, with overall agreement at 93.5%, substantial concordance (κ ¼ 0.78), and good PPV (77.3%). The titration intolerance algorithm in the low CV-risk cohort also showed substantial concordance (κ ¼ 0.68) and good sensitivity (83.8%), but modest PPV (60.8%). NPV was uniformly high, ranging from 95% to 99%. Although the frequency of SI in the secondary analysis was similar to that in the primary analysis, Patients were selected randomly to preserve the 80/20 split between moderate-to low-intensity and high-intensity statin patients observed in the administrative database, with 40% on simvastatin, 40% on atorvastatin, and 20% on other statins. ‡ Ten patients were excluded because of data quality issues. § Patients with a diagnosis of diabetes, coronary heart disease, or peripheral artery disease in the 12 mo before the qualifying event.
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Discussion
This study is the first to develop and validate algorithms for the identification of SI in an administrative database. Definitions of SI used in these algorithms align with those endorsed by the NLA Statin Intolerance Panel [22] and the CWG [21] and are an essential ingredient in characterizing the clinical, economic, and quality-of-life burdens associated with SI. The algorithms successfully identified both absolute and titration intolerance in a population of patients at high CV risk. The algorithm for any SI demonstrated substantial concordance (κ ¼ 0.73), sensitivity (80.9%), PPV (75.3%), and NPV (95.4%), despite marginal performance in the absolute intolerance portion of the algorithm. In this study, the titration intolerance algorithm performed best in patients with high CV risk, as evidenced by its substantial concordance (κ ¼ 0.78), high NPV (97.2%) and sensitivity (86.4%), and good PPV (77.3%). There was also a higher incidence of SI in patients with high CV risk than in patients with low CV risk.
On the basis of the results, the algorithms performed comparably to other CV algorithms previously developed for administrative data. Thacker et al. [28] developed an algorithm to identify patients at high risk for coronary heart disease events (PPV 87%; sensitivity 69%; specificity 90%). Hsieh et al. [29] validated a claims-based algorithm to measure the incidence of acute ischemic stroke (PPV 88%; sensitivity 97%; specificity not reported). Numerous algorithms have been developed to identify heart failure (PPV 84%-100%; sensitivity 33%-83%) [30] , whereas one study assessing CV outcomes has reported kappa statistics ranging from 0.71 to 0.91 [31] .
Both the reference definition and SI algorithms developed in the course of this study reflect SI definitions of the CWG [21] and ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PAD, peripheral artery disease. * High-intensity statin: atorvastatin 40 or 80 mg; rosuvastatin 10, 20, or 40 mg; and simvastatin 80 mg. † Other prescribed LLTs included cholestyramine, clofibrate, colesevelam, colestipol, ezetimibe, fenofibrate, fenofibric acid, gemfibrozil, niacin, omega-3-acid ethyl esters, and probucol. the NLA Statin Intolerance Panel [22] by requiring statin rechallenge when appropriate clinically [19, 21, 22] and some evidence of an AE during the period of statin exposure, regardless of whether the presenting symptom was "real or perceived" [22] . In addition, the reference EMR definition required that the documented AE be temporal in nature and attributed to the initiation or dose escalation of statins. Nevertheless, one element of the NLA definition was not included in either the reference definition or in the algorithms, that is, the requirement that one of the two statins administered be at the lowest starting daily dose. Moreover, the SI algorithms did not require exclusion of other known determinants of an AE, such as hypothyroidism, concurrent illness, drug interaction, or muscle disease underlying a change in physical activity [22] . In addition, these algorithms did not require symptom reversal upon statin discontinuation or dose lowering [21, 22] . Although the study definitions incorporated the best consensus definition available when the algorithms were developed, the definitions of SI and the guidelines for the management of hypercholesterolemia continue to evolve. Recently, the International Lipid Expert Panel proposed a unified definition of SI, which includes statin rechallenge and a link with confirmed statin-related, muscle-based AEs [19] . Likewise, the treatment guidelines for hypercholesterolemia changed during the course of this study. For example, the 2013 American College of Cardiology/ American Heart Association guidelines consider rosuvastatin 10 mg a moderate-intensity statin [3] , whereas in this study rosuvastatin is classified as a high-intensity statin. Nevertheless, rosuvastatin 10 mg has demonstrated high efficacy in lowering LDL-C (up to 52% reduction) [23, 32] .
The algorithms described in this report performed best in patients at high CV risk. These patients are most likely to benefit from lipid-lowering therapy in terms of reduced CV event risk and as such are at the greatest risk for poor outcomes as a result of inadequate LDL-C reduction due to SI. In addition, these patients require close monitoring, especially early in their therapy, because statin-associated muscle AEs occur most frequently within the first 6 months of statin therapy initiation [33] . The diagnosis of SI can, however, be challenging because patients may be seen by clinicians infrequently, may not be clear in describing their symptoms (e.g., joint pain instead of muscular pain), may minimize symptom severity, may present atypically or with symptoms associated with other conditions and/or medications, or may be noncompliant with statins prescribed as part of the rechallenge. In addition, providers may be more focused on treating other urgent health concerns. All these scenarios may contribute to a delay in identifying and remediating SI.
The ability to measure SI in large, real-world data sets can expedite identification of the predictors of SI and enable earlier, more effective intervention. At the practice level, this could result in a targeted intervention for patients at high risk for SI, improving patient outcomes and facilitating a more efficient allocation of valuable primary care resources. At the payer level, an enhanced understanding of the role of SI in patient adherence could inform both care and medication management programs. For researchers, the present algorithm serves as the basis for the development of more sophisticated probabilistic models.
Although standards for what constitutes adequate sensitivity, specificity, PPV, and NPV have not yet been established, the sensitivity associated with the absolute intolerance algorithm is likely too low (50%) to support studies of incidence or prevalence. In contrast, the NPV is sufficiently high (99%) to cull a sample of statin users for whom there is no evidence of absolute intolerance. In the absence of standards establishing minimum thresholds for what constitutes a validated algorithm, researchers must determine whether an algorithm reporting a sensitivity of 86% is adequate to detect disease incidence or whether a PPV of 77% is adequate to cull a cohort of patients with titration intolerance. Until such standards are established, the authors encourage researchers to consider using sensitivity analyses as appropriate.
Researchers should consider a number of other factors before implementing this algorithm. Algorithm performance may not be generalizable across data sources if coding systems differ across populations. The present study was predicated, in part, on the definition of CV risk. Algorithm performance may vary if alternate definitions of high CV risk are used.
The rate of SI observed in the present study cannot be generalized to all statin users because the study was based on a population of patients who had experienced at least one change in statin therapy. Nevertheless, extrapolation to all eligible HFHS patients suggests an overall SI rate between 4% and 6%, an estimate that is at the lower end of the real-world range reported for muscle-related AEs (5%-25%) [6, [13] [14] [15] [16] [17] [18] . Given the existing literature and the likelihood that symptoms and diagnoses may be underreported if such documentation on a claim will not result in an increase in reimbursement, we believe that the algorithms may produce a conservative estimate of SI.
Zhang et al. [17] used EMR to investigate reasons for statin discontinuation and found that more than half of the study patients discontinued at least one statin but that, among those who were rechallenged, more than 90% remained actively on statin therapy 12 months after a statin-related event. The study, however, focused only on statin discontinuation and analyzed only the first-reported statin-related event. Similarly, Robison et al. [34] used the Intermountain Healthcare EMR database to identify patients with a documented history of SI with and without hypothyroidism. The algorithm, however, was not validated and had numerous other limitations: patients were not required to have a minimum duration of statin therapy; there was no requirement to attempt therapy with more than one statin; the analysis was conducted in a predominantly white population; and the study did not collect information on the specific statins taken by patients or on statin dosage.
The strength of the present study includes the ability to compare data iteratively between a clinically rich EMR and an administrative database. This facilitated the creation and refinement of algorithms to identify SI in a diverse patient population, receiving services in various practice settings. Furthermore, the definition of SI is comprehensive, reflecting the consensus statement of two key organizations and incorporating important clinical elements, such as statin rechallenge, statin intensity, temporal AEs, and a differential threshold for patient cases with rhabdomyolysis. Stratification by CV-risk status revealed the differential performance of the algorithms, which are not without limitations. Definitions of SI in both the administrative database and the EMR relied on sufficient documentation in both data sources. Administrative data were dependent on the documentation of a symptom or a diagnosis on a claim for reimbursement, and our gold standard EMR definition required documentation of the symptom in the medical record. Misclassification may also have occurred if patients filled statin prescriptions outside of insurance programs, if there were numerous verbal changes in prescriptions that were not reflected at the pharmacy, or if clinician concern over low LDL-C levels or patients' financial constraints resulted in dosage lowering.
Conclusions
The validated and comprehensive algorithms presented herein make possible the identification of SI from US administrative databases. These are the first validated algorithms for use in administrative databases to be made available to decision makers.
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